EqualOcean has learned that DP Technology（深势科技）, an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital（众源资本）, MSA Capital（和玉资本）, Loyal Valley Capital（正心谷资本）, Evergreen Scitech Delta（深势科技）, and many other industry-specific investors, with Lighthouse Capital（光源资本） serving as the exclusive financial advisor.
Established in 2018 and headquartered in Beijing, DP Technology is dedicated to pioneering a new era in scientific research using "AI for Science." Their focus lies in creating a next-generation, multiscale simulation and industrial infrastructure platform for fundamental research in fields as foundational to human civilization as biomedicine, energy, materials, and information science and engineering.
Since its inception, DP Technology has ceaselessly innovated and executed its vision. In recent years, it has entered a fast lane of scalable and commercial development, emerging as a key player in the "AI for Science" sector. They have introduced a series of computational engines and pre-trained models addressing fundamental scientific challenges such as micro and mesoscale simulation, molecular property prediction, and experimental characterization optimization. These serve as the foundation for their R&D solutions driven by AI and computational simulation in fields like scientific research, pharmaceuticals, and battery technologies. Additionally, they have rapidly established an open ecosystem and an industrial cooperation system based on "AI for Science."
AI in pharmaceutical research applies artificial intelligence technologies like machine learning, natural language processing, and big data to various stages of drug development to enhance cost-efficiency. Over the past year, DP Technology and its collaborators have released a series of significant technological achievements and upgraded the infrastructure of "AI for Science," integrating this technology into the pre-training model stage.
The global AI pharmaceutical research sector is experiencing continuous growth, with North America hosting the largest market share. The United States is home to over 50% of AI pharmaceutical research companies globally. It is projected that the global AI pharmaceutical research market will reach USD 3.88 billion by 2025, with North America leading the way and the Asia-Pacific region ranking third. Currently, there are around 700 AI pharmaceutical research companies worldwide, with over 50% located in the United States. The United Kingdom and the European Union represent 12.5% and 13.4%, respectively, while China accounts for approximately 4.7%.
EqualOcean has learned that most Chinese AI pharmaceutical research companies are still in their early-stage financing phases, including Evergreen Therapeutics（埃格林医药）,XtalPI（晶泰科技）, Galixir（星药科技）, ReviR Therapeutics（溪砾科技）, and Insilico Medicine（英矽智能）, among others.
The funds raised in this round of financing by DP Technology will primarily be used to attract top talents, further strengthen their full-stack capabilities, from algorithmic innovation to industrial software and industry-specific solutions. Simultaneously, they will intensify the industrialization and commercialization of related technologies in fields such as biomedicine, new energy, chemicals, semiconductors, and more.